Percent of all patients on oral monotherapy (68.6%)

- Metformin: 79.0%
- Sulfonylureas: 14.8%
- Glucosidase inhibitors: 2.4%
- Glinides: 2.3%
- Glitazones: 0.8%
- DPP-4 Inhibitors: 0.6%

Percent of all patients on dual oral combination therapy (31.4%)

- Metformin
- Glucosidase inhibitors
- Sulfonylureas
- Glinides
- Glitazones
- DPP-4 Inhibitors